Skip to main content

Allscripts Healthcare Solution Value Stock - Dividend - Research Selection

Allscripts healthcare solution

ISIN: US01988P1084 , WKN: 607917

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Allscripts Healthcare Solutions, Inc. provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions. The company\'s Clinical and Financial Solutions segment provides integrated clinical software applications and financial and information solutions, which primarily include EHR-related, and financial and practice management software solutions, as well as related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training, and electronic claims administration services. Its Population Health segment offers health management and coordinated care solutions that enable hospitals, health systems, accountable care organizations, and other care facilities to connect, transition, analyze, and coordinate care across the entire care community. The company\'s Netsmart segment operates in and provides software and technology solutions to the health and human services, and post-acute sectors of health care. The company serves physicians, hospitals, governments, health systems, health plans, life-sciences companies, retail clinics, retail pharmacies, pharmacy benefit managers, insurance companies, and employer wellness clinics, as well as post-acute organizations, such as home health and hospice agencies. Allscripts Healthcare Solutions, Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Veradigm : Material Event - Form 8-K

2024-04-10
Item 8.01 Other Events. As previously disclosed, The...

Veradigm Network Solution Practice Fusion EHR Receives Top Ambulatory Rankings

2024-04-09
CHICAGO, April 09, 2024--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Practice Fusion first for Ambulatory EHR PM Family Practice and Ambulatory EHR PM Primary Care General Practice within its 2024 Top Client/User-Rated Electronic Health Records & Practice Management Solutions report.

Veradigm announces strategic collaboration with Vim

2024-04-03
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Veradigm : Material Agreement - Form 8-K

2024-04-01
Item 1.01 Entry into a Material Definitive Agreement. ...

Update in Lawsuit for Investors who purchased shares of Veradigm Inc. (NASDAQ: MDRX) announced by the Shareholders Foundation

2024-03-26
SAN DIEGO, March 26, 2024 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in Veradigm Inc., f.k.a. Allscripts Healthcare Solutions, Inc....

Veradigm just downgraded at Deutsche Bank, here's why

2024-03-19
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Veradigm’s Challenging Outlook: Hold Rating Justified Amid Revenue Growth, Margin Pressures, and Audit Concerns

2024-03-19
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Analysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)

2024-03-15
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Veradigm to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

2024-03-14
CHICAGO, March 14, 2024--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions announced today that Dr. Yin Ho, Veradigm Interim Chief Executive Officer and board member, Lee Westerfield, Interim Chief Financial Officer, and Will Manidis Co-Founder of ScienceIO will participate in a fireside chat at the KeyBanc Capital Markets Life Science & MedTech Investor Forum on Tuesday, March 19th, 2024 at 12:00 PM EDT.

Veradigm Announces Initial Financial Guidance for Fiscal 2024

2024-03-13
CHICAGO, March 13, 2024--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today it has reaffirmed the estimated, unaudited ranges for fiscal 2023 of GAAP Revenue, Adjusted EBITDA, and Non-GAAP diluted earnings per share that it provided on January 10, 2024, in the Company’s Form 8-K filed on January 10, 2024, and initially reaffirmed on February 27, 2024.